Combined regulation of pro-inflammatory cytokines production by STAT3 and STAT5 in a model of B. pertussis infection of alveolar macrophagesFRONTIERS IN IMMUNOLOGYIF5.92023-09-280OAAI
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation studyLANCET INFECTIOUS DISEASESIF312020-11-0140OAAI
Manufacture of a Stable Lyophilized Formulation of the Live Attenuated Pertussis Vaccine BPZE1VACCINESIF3.42020-09-136OAAI
Early Protection against Pertussis Induced by Live Attenuated Bordetella pertussis BPZE1 Depends on TLR4JOURNAL OF IMMUNOLOGYIF3.42019-12-1519OAAI
PERISCOPE: road towards effective control of pertussis潜望镜: 有效控制百日咳的道路LANCET INFECTIOUS DISEASESIF312019-05-0156OAAI
Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and InfectionJOURNAL OF INFECTIOUS DISEASESIF4.52017-05-2369OAAI
Live attenuated B-pertussis as a single-dose nasal vaccine against whooping coughPLOS PATHOGENSIF4.92006-07-07177OAAI
Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S-mansoni-infected miceSCANDINAVIAN JOURNAL OF IMMUNOLOGYIF1.62002-01-1318OAAI
Nasal vaccination using live bacterial vectors使用活细菌载体的鼻疫苗接种ADVANCED DRUG DELIVERY REVIEWSIF17.62001-09-0144PREAI
Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussisNATURE BIOTECHNOLOGYIF41.71998-05-0172OAAI
Local transient induction of inflammatory cytokines after intranasal administration of recombinant Bordetella pertussisMICROBIAL PATHOGENESISIF3.51997-05-013PREAI
Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussisPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.11996-07-2360OAAI